Semaglutide inonzi polypeptide iyo vanachiremba vanorayira kurapwa kwechirwere cheshuga 2.Iyo FDA yakabvumidza kushandiswa kweNovo Nordisk's Ozempic neRybelsus sejekiseni kamwe chete pavhiki kana sehwendefa, zvichiteerana.Jekiseni kamwe-pavhiki remaglutide rine zita rezita rekuti Wegovy richangobva kubvumidzwa sekurapa uremu.
Tsvagiridzo nyowani yakapihwa gore rino European Congress on Obesity (ECO2023, Dublin, 17-20 Chivabvu) inoratidza kuti kufutisa mushonga semaglutide inoshanda pakurasikirwa nehuremu mune yakawanda-yakareba, 1-gore-yakareba-chaiyo nyika kudzidza.Chidzidzo ichi chakaitwa naDr Andres Acosta naDr Wissam Ghusn, Precision Medicine for Obesity Programme paMayo Clinic, Rochester, MN, USA nevamwe vashandi.
Semaglutide, glucagon-like peptide-1 (GLP-1) receptor agonist, ndiyo ichangoburwa FDA-inotenderwa anti-obesity mishonga.Yakaratidza mhedzisiro yekurasikirwa kwehuremu mune akawanda-refu-randomized kliniki miedzo uye yenguva pfupi-yechokwadi-yenyika zvidzidzo.Nekudaro, zvishoma zvinozivikanwa nezvehuremu uye metabolic paramita mhedzisiro yepakati-temu chaiyo-yenyika zvidzidzo.Muchidzidzo ichi, vanyori vakaongorora kuora kurasikirwa kwemigumisiro yakabatana ne semaglutide kune varwere vane kuwandisa uye kuneta uye uye vasina rudzi rwechirwere cheshuga 2 (T2DM) mugore re1 kutevera.
Vakaita retrospective, multicentre (Mayo Clinic Hospitals: Minnesota, Arizona, uye Florida) kuunganidza data pamusoro pekushandiswa kwe semaglutide pakurapa kufutisa.Vaisanganisira varwere vane body mass index (BMI) ≥27 kg / m2 (kuwandisa uye ese akakwirira BMI mapoka) avo vakanyorerwa vhiki nevhiki semaglutide subcutaneous jekiseni (doses 0.25, 0.5, 1, 1.7, 2, 2.4mg; zvisinei vazhinji vakanga varipo. muyero wepamusoro 2.4mg).Vaisabatanidza varwere vanonwa mimwe mishonga yekufutisa, vane nhoroondo yekuvhiyiwa kufutisa, vane gomarara, uye vaive nepamuviri.
Mhedziso yekupedzisira yaive yakazara uremu hwemuviri kurasikirwa muzana (TBWL%) pa1 gore.Sekondari yekupedzisira mapoinzi aisanganisira chikamu chevarwere vanowana ≥5%, ≥10%, ≥15%, uye ≥20% TBWL%, shanduko yemetabolism uye yemwoyo parameters (BP, HbA1c [glycated hemoglobin, chiyero chekudzora shuga muropa], kutsanya glucose nemafuta eropa), TBWL% yevarwere vane uye vasina T2DM, uye kuwanda kwemigumisiro mukati megore rokutanga rekurapa.
Zvose zvevarwere ve305 zvakabatanidzwa mukuongorora (73% yevakadzi, makore anoreva makore 49, 92% machena, anoreva BMI 41, 26% neT2DM).Baseline hunhu uye huremu manejimendi yekushanya ruzivo runoratidzwa muTafura 1 yakazara abstract.Muchikwata chese, zvinoreva TBWL% yaiva 13.4% pa 1 gore (kune varwere ve110 vaiva nehuremu data pa 1 gore).Varwere vane T2DM vaiva neTBWL yakaderera% ye10.1% ye45 yevarwere ve110 vane data pa 1 gore, zvichienzaniswa nevasina T2DM ye16.7% ye65 yevarwere ve110 vane data mugore re1.
Nhamba yevarwere vakarasikirwa nepamusoro pe5% yehuremu hwemuviri wavo yaive 82%, inopfuura 10% yaive 65%, inopfuura 15% yaive 41%, uye inopfuura 20% yaive 21% pagore 1.Semaglutide kurapwa zvakare yakaderera zvakanyanya systolic uye diastolic blood pressure ne 6.8 / 2.5 mmHg;cholesterol yakazara ne10.2 mg/dL;LDL ye5.1 mg/dL;uye triglycerides ye17.6 mg/dL.Hafu yevarwere vakawana mhedzisiro ine chekuita nekushandiswa kwemushonga (154/305) uye yakanyanya kutaurwa kuve kusvotwa (38%) uye manyoka (9%) (Mufananidzo 1D).Migumisiro yacho yainyanya kupfava isingakanganisi kunaka kwehupenyu asi muzviitiko zve16 zvakaguma nekumisa mushonga.
Vanyori vanogumisa kuti: "Semaglutide yaibatanidza kurasikirwa kukuru kwehuremu uye kuvandudzwa kwemasabolism parameters mugore re1 mune imwe nzvimbo yakawanda yekudzidza kwenyika-yechokwadi, ichiratidza kubudirira kwayo mukurapa kufutisa, kune varwere vane uye vasina T2DM."
Chikwata cheMayo chiri kugadzirira mamwe manyoro akawanda ane chekuita nesemaglutide, kusanganisira uremu mhedzisiro muvarwere vaive nekuremerwa kwekudzoka mushure mekuvhiyiwa kwebariatric;Kurasikirwa kwehuremu mhedzisiro muvarwere vaive pane mamwe anti-obesity mishonga yakamboenzaniswa nevaya vasina.
Nguva yekutumira: Sep-20-2023